Medical News

Retatrutide Trial 3 Results

Retatrutide Delivers Remarkable Weight Loss in Landmark Phase 3 Trial Published: June 2026   A new investigational obesity medication may represent the next major breakthrough in weight management. Eli Lilly recently announced results from the Phase 3 TRIUMPH-1 clinical trial showing that retatrutide, an experimental once-weekly injection, produced average weight loss approaching 30% of body

Retatrutide Trial 3 Results Read More »

FDA Warns About Unapproved GLP-1 Weight Loss Drugs:

FDA Warns About Unapproved GLP-1 Weight Loss Drugs: What Patients Need to Know Published: June 2026   The U.S. Food and Drug Administration (FDA) has issued an updated safety communication warning consumers about the growing number of unapproved GLP-1 medications being sold for weight loss. While medications such as semaglutide and tirzepatide have transformed the

FDA Warns About Unapproved GLP-1 Weight Loss Drugs: Read More »